i m ann marie walker. i m alex march quart in for boris sanchez. the house of representatives finally elects a speaker. how kevin mccarthy gets the votes. remarkable progress for damar hamlin and the moment he face timed his teammates from his hospital bed. and new details on the horrific murder of four idaho college students. what we re learning from a recently released affidavit and the father of one of the victims tells cnn why he believes the group was targeted. plus, the fda grants approval for a new alzheimer s drug. the reported benefits and the concern coming up on cnn this morning. it is saturday, january 7th. thank you so much for waking up with us. thank you so much for having me back. alex, it s great to be with you. we re matching. we re in lock step together. good to be with you, alex. happy new year. and to you. thank you so much. who needs reality tv when you have cspan. cnn after days of deadlock, 15 ballots and a lot of deal making, republi
the gentleman from the state of california and the next speaker of the 118th congress, kevin mccarthy. [ cheers and applause ] kevin mccarthy grabbing the gavel after 15 rounds of voting. it was the longest speaker contest in 164 years. despite sometimes contentions and negotiations with the narrow faction of his conference, republicans in the end rallied around mccarthy and his vision for america. i make this promise i ll never give up for you, the american people. and i will never give up on keeping our commitment to america. our nation is worth fighting for. our rights are worth fighting for. our dreams are worth fighting for. cnn s eva mckend is live on capitol hill. eva, what finally pushed mccarthy over the edge for these republican holdouts? reporter: well, he was able to convince those never-kevin lawmakers ultimately vote present and that is how he secured this victory on the 15th try, fred, but also by making some key concessions. so, for instance, those
concessions he made to them in order to get their votes? reporter: jake, that is really starting to come into focus. the number of concessions and promises that kevin mccarthy has made over the course of the negotiations has been quite outstanding, and i should caution that this stuff has not been put on paper. there has not been anything put out that we have seen. this is based on the reporting from me and my fantastic hill team. but i just want to walk you through just to give the viewers a sense of what has been agreed to and what a kevin mccarthy speakership could look like. the big one is he agreed for any single member to be able to call for a vote on ousting the sitting speaker. that s something he used to say he would never budge on. now any member could call for that vote. he s agreed that his leadership pack is not going to play in primaries to try to beat conservatives, at least in safe districts. that s something conservatives have complained about in the past.
bleeding. cohen says these types of side effects were mostly mild in the trial. we do know that this has a low ratde of causing macro hemorrhage, a low rate less than 1%. in the phase 3 clinical trial there were seven deaths in the placebo group and six in the drug group. according to investigators though, none of the drugs were said to be due to the drug or aria. the new england journal of i had medicine published an additional death of a patient who had been given blood thinners. it s difficult to say it was the drug when another drug can cause significant bleeding. reporter: they agree while this drug shows promise, it must come with caution. for example, avoiding blood thinners while taking the medication. i will prescribe this drug in
reporter: dr. sharon cohen has been studying alzheimer s drugs for 30 years and was part of the clinical trials for lecanemab. what she is talking about is amyloid originating abnormality. it can look like this or this. it s brain swelling or brain bleeding. know cohen says these types of side effects were mostly mild in the trial. we do know that lecanemab has a low rate of causing macro hemorrhage, not necessarily fatal, but a low rate, less than 1%. reporter: in the phase three clinical trial, there were seven deaths in the placebo group and six deaths in the lecanemab group. according to the investigators, though, none of the deaths were considered to be due to lecanemab or a.r.e.a. the new england journal of medicine recently published details of an additional death of ooh patient on the drug who had been given blood thinners, raising additional concerns. it s pretty hard to say lecanemab caused that when we re